加载中
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
前收盘价
US$35.20
−US$1.70 · -4.61%
盘前
US$35.35
+US$0.15 · +0.43%
10月13日 4:01 ET
盘中时间采用ET。市场数据可能有所延迟。
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
日内区间
当前US$35.20
52周区间
当前US$35.20
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
32
偏贵
情绪
51
多空交织
风险
51
风险偏高
动量
64
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
日内区间
当前US$35.20
52周区间
当前US$35.20
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 52.7万 USD | 316.2万 USD | — | — |
| 毛利 | — | −52.7万 USD | −316.2万 USD | — | — |
| 研究与开发 | 1.18亿 USD | 6529.7万 USD | 4896.2万 USD | 3616.9万 USD | 3478.9万 USD |
| 销售、一般及管理费用 | 4864.4万 USD | 3861.9万 USD | 4174.2万 USD | 3016.2万 USD | 5906.5万 USD |
| 营业费用 | 1.66亿 USD | 1.03亿 USD | 9070.4万 USD | 6633.1万 USD | 9385.4万 USD |
| 利息收入 | 1096万 USD | 1155.8万 USD | 558.4万 USD | 149.5万 USD | — |
| 利息支出 | 548.2万 USD | 228.3万 USD | 92万 USD | 149.5万 USD | 35.9万 USD |
| 折旧和摊销 | — | 52.7万 USD | 316.2万 USD | 318万 USD | 261.6万 USD |
| 营业利润 | −1.66亿 USD | −1.04亿 USD | −9386.6万 USD | −6633.1万 USD | −9385.4万 USD |
| 净利润 | −1.84亿 USD | −1.09亿 USD | −9573.2万 USD | −5679.6万 USD | −9303.6万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM1.21亿0.15%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF5984.78万0.06%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO4265.25万0.31%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB3673.49万0.34%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO2971.1万0.16%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA2502.08万0.12%217.13亿 USD0.03%US$32.66-0.40%
iShares U.S. Pharmaceuticals ETFIHE1725.82万1.11%15.52亿 USD0.37%US$100.19+0.10%
Fidelity Enhanced Small Cap ETFFESM1593.2万0.24%64.1亿 USD0.28%US$45.24-0.48%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
